American journal of nuclear medicine and molecular imaging最新文献

{"title":"Noninvasive PET imaging of tumor PD-L1 expression with ⁶⁴Cu-labeled Durvalumab.","authors":"Sara Malih, Wilson Lin, Zhongmin Tang, Molly C DeLuca, Jonathan W Engle, Behrouz Alirezapour, Weibo Cai, Mohammad J Rasaee","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Breast cancer (BrCa) ranks as the most prevalent malignant neoplasm affecting women worldwide. The expression of programmed death-ligand 1 (PD-L1) in BrCa has recently emerged as a biomarker for immunotherapy response, but traditional immunohistochemistry (IHC)-based methods are hindered by spatial and temporal heterogeneity. Noninvasive and quantitative PD-L1 imaging using appropriate radiotracers can serve to determine PD-L1 expression in tumors. This study aims to demonstrate the viability of PET imaging with ⁶⁴Cu-labeled Durvalumab (abbreviated as Durva) to assess PD-L1 expression using a murine xenograft model of breast cancer. Durvalumab, a human IgG1 monoclonal antibody against PD-L1, was assessed for specificity <i>in vitro</i> in two cancer cell lines (MDA-MB-231 triple-negative breast cancer cell line and AsPC-1 pancreatic cancer cell line) with positive and negative PD-L1 expression by flow cytometry. Next, we performed the <i>in vivo</i> evaluation of ⁶⁴Cu-NOTA-Durva in murine models of human breast cancer by PET imaging and <i>ex vivo</i> biodistribution. Additionally, mice bearing AsPC-1 tumors were employed as a negative control. Tumor uptake was quantified based on a 3D region-of-interest (ROI) analysis of the PET images and <i>ex vivo biodistribution</i> measurements, and the results were compared against conventional IHC testing. The radiotracer uptake was evident in MDA-MB-231 tumors and showed minimal nonspecific binding, corroborating IHC-derived results. The results of the biodistribution showed that the MDA-MB-231 tumor uptake of ⁶⁴Cu-NOTA-Durva was much higher than ⁶⁴Cu-NOTA-IgG (a nonspecific radiolabeled IgG). In Conclusion, ⁶⁴Cu-labeled Durvalumab PET/CT imaging offers a promising, noninvasive approach to evaluate tumor PD-L1 expression.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":"14 1","pages":"31-40"},"PeriodicalIF":2.5,"publicationDate":"2024-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10944374/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140157399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular imaging reveals the heterogeneous progression of tumor cells and tumor stroma: a practice of FDG PET and FAPI PET in diagnosing PSMA-negative bone metastases of progressive prostate cancer.","authors":"Lizhi Zhu, Peng Chen, Zhongqiu Guo, Fangdu Li, Xiu Luo, Xia Du, Liying Zhang, Changjing Zuo, Xiao Li","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Tumors are often with complex and heterogeneous biological processes, such as glycometabolism and fibrosis, which are the main biochemical pathways that determine therapeutic effects. Specifically, this study aims to assess the diagnosing performance of ¹⁸F-FDG and ⁶⁸Ga-FAPI-04 PET for different stages of progressive bone metastases with PSMA-negative pathology. Bone metastatic mouse model of prostate cancer was constructed via intra-bone injection of PSMA-negative prostate cancer PC3 cells. Cellular uptakes of ¹⁸F-FDG and ⁶⁸Ga-FAPI-04 were separately performed on PC3, NIH-3T3 (FAP-positive) and a mixture. ⁶⁸Ga-PSMA-11, ¹⁸F-FDG and ⁶⁸Ga-FAPI-04 PET/CT imaging were performed at 2, 4 weeks after tumor cell transplantation. Furthermore, PSMA and FAP expression in bone metastases were assessed by immunohistochemistry, and then compared with the imageological findings. On the cellular level, the independent tracer uptake on the basis of glycometabolism and fibrosis was observed. For animal imaging, ⁶⁸Ga-PSMA-11 imaging showed weak or absent tracer uptake in PSMA-negative bone metastatic lesions. In contrast, ⁶⁸Ga-FAPI-04 PET of bone metastases had a higher uptake and tumor-to-muscle (T/M) ratio than ¹⁸F-FDG PET that was relative steady during the observation, but T/M ratio of fibrosis gradually decreased with increasing tumor growth, which ranged from 5.11 ± 1.26 at 2 weeks to 3.54 ± 0.23 at 4 weeks, revealing the delayed formation of tumor stroma in rapid proliferation. In addition, PET imaging results were corroborated by immunohistochemical assessment. In conclusion, molecular imaging approach revealed the heterogeneous progression of tumor cells and tumor stroma of bone metastasis of prostate cancer, and further confirming the necessity of multi-molecular imaging in cancer imaging.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":"14 1","pages":"13-21"},"PeriodicalIF":2.5,"publicationDate":"2024-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10944373/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140157398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Two decades of [¹¹C]PiB synthesis, 2003-2023: a review.","authors":"Paul Josef Myburgh, Kiran Kumar Solingapuram Sai","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Because carbon-11 (¹¹C) radiotracers cannot be shipped over long distances, their use in routine positron emission tomography (PET) studies is dependent on the production capabilities of individual radiochemistry laboratories. Since 2003, ¹¹C-labeled Pittsburgh compound B ([¹¹C]PiB) has been the gold standard PET radiotracer for <i>in vivo</i> imaging of amyloid β (Aβ) plaques. For more than two decades, researchers have been working to develop faster, higher-yielding, more robust, and optimized production methods with higher radiochemical yields for various imaging applications. This review evaluates progress in [¹¹C]PiB radiochemistry. An introductory overview assesses how it has been applied in clinical neurologic imaging research. We examine the varying approaches reported for radiolabeling, purification, extraction, and formulation. Further considerations for QC methods, regulatory considerations, and optimizations were also discussed.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":"14 1","pages":"48-62"},"PeriodicalIF":2.5,"publicationDate":"2024-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10944378/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140157400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unexpected ^99mTc-pertechnetate avidity of lymph node metastases predicts better response to radioiodine therapy in differentiated thyroid cancer patients with lymph node metastases.","authors":"Jie Liu, Xin Li, Linfa Li, Yuhua Yin, Hu Cai, Heqing Yi","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the value of ^99mTc-pertechnetate scan in postoperative differentiated thyroid cancer (DTC) patients with lymph node (LN) metastases (LNM) uptake ^99mTc-pertechnetate, especially the predictive value to their response to radioiodine-131 (¹³¹I) therapy.</p><p><strong>Methods: </strong>This retrospective study collected 752 patients with DTC and LNM treated at Zhejiang Cancer Hospital between May 2012 and December 2017. Depending on the ability of LNM uptake ^99mTc-pertechnetate, the patients were grouped as the ^99mTc-pertechnetate-avid (n=88) vs. ^99mTc-pertechnetate-non-avid (n=664) groups. And Propensity score matching (PSM) was performed at a 1:4 ratio to reduce confounding bias.</p><p><strong>Results: </strong>In the PSM analysis, the 1:4 matched cohort comprised 752 patients (88 with ^99mTc-pertechnetate-avid LNM, 664 with ^99mTc-pertechnetate-non-avid LNM). Patients' age, initial ¹³¹I activity and frequency of iodine therapy were included as covariates. After PSM analysis, 363 patients (^99mTc-pertechnetate-avid group, n=83; ^99mTc-pertechnetate-non-avid group, n=280) were successfully matched. Among the 363 PSM-matched patients, 48/83 (57.8%) in the ^99mTc-pertechnetate-avid group and 158/280 (56.4%) in the ^99mTc-pertechnetate-non-avid group had two or more ¹³¹I treatments. The nsTg and the percentage of changes in ssTg between the ^99mTc-pertechnetate-avid and ^99mTc-pertechnetate-non-avid groups were significantly different ([0.05 (0.04 to 0.90) vs. 0.40 (0.04 to 4.92), <i>p</i>=0.018] and [-88% (-98%, -50%) vs. -66% (-86%, -30%), <i>p</i> < 0.001], respectively). No significant differences were observed between the two groups in the other parameters (age, pathological type, distant metastasis, follow-up time, AJCC TNM stage, initial ¹³¹I treatment activity, and ¹³¹I treatment frequency) after PSM (all <i>p</i> > 0.05).</p><p><strong>Conclusion: </strong>In patients with DTC and LNM, LNM uptake of ^99mTc-pertechnetate is a rare phenomenon. Patients with ^99mTc-pertechnetate-avid LNMs were more likely to benefit from ¹³¹I therapy, even after adjustment for age, ¹³¹I treatment frequency, and initial ¹³¹I activity.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":"14 1","pages":"63-71"},"PeriodicalIF":2.5,"publicationDate":"2024-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10944372/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140157401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"¹⁸F-FDG PET/CT in extranodal natural killer/T-cell lymphoma: a comprehensive evaluation method.","authors":"Xiaoyue Zhang, Wenpeng Huang, Yongkang Qiu, Zhao Chen, Lele Song, Qi Yang, Lei Kang","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Extranodal NK/T-cell lymphoma (ENKTL) is an uncommon subtype of non-Hodgkin's lymphoma that is closely related to Epstein-Barr virus (EBV) infection. ENKTL exhibits distinctive clinicopathological features among lymphomas and has poor overall survival in the absence of effective treatment. The timely and accurate diagnosis of ENKTL is crucial for effective treatment and a positive prognosis. ¹⁸F-Fluorodeoxyglucose-positron emission tomography/computed tomography (¹⁸F-FDG PET/CT) has emerged as an invaluable diagnostic modality for staging, curative effect evaluation, and prognosis analysis in ENKTL. We herein provide a comprehensive overview of the advances in the application of ¹⁸F-FDG PET/CT in patients with ENKTL.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":"13 6","pages":"245-258"},"PeriodicalIF":2.5,"publicationDate":"2023-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10774604/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139416086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnosis and prognostic predictive value of delineation methods from ¹⁸F-FDG PET/CT and PET/MR in pancreatic lesion.","authors":"Fan Hu, Xiao Zhang, Hua Shu, Xiaoli Wang, Shuqian Feng, Mengmeng Hu, Xiaoli Lan, Chunxia Qin","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The aim was to utilize three segmentation methods on ¹⁸F-FDG PET/CT and PET/MR images of pancreatic neoplasm patients, and further compare the effectiveness in differentiating benign from malignant, TNM-stage and prognosis. We conducted a retrospective analysis of 51 patients with pancreatic neoplasm who had undergone ¹⁸F-FDG PET/CT and PET/MR before treatment. The patients were categorized into malignant and benign groups. For each patient, the lesion was segmented by 3 thresholds and we recorded TNM-stage, treatment strategy, time to death, and the performance status of survivors. We used receiver operating characteristic (ROC) analysis to compare the diagnostic performance of different threshold delineations between benign and malignant, as well as TNM-stage of adenocarcinoma patients. The optimal model of prognostic value was also assessed by Cox proportional hazards regression analysis and Kaplan-Meier survival analysis. For both PET/CT and PET/MR, SUV_max had the best diagnostic efficacy in identifying malignant tumors. The background method of PET/MR exhibited the outstanding performance in M-stage (sensitivity/specificity, 92.90%/88.20%), with the weighted factor being whole-body total lesion glycolysis (WBTLG). In multivariate analysis, WBTLG (Exp [B] = 1.009; <i>P</i> = 0.009), and surgery (Exp [B] = 15.542; <i>P</i> = 0.008) were independent predictive factors associated with prognosis. This study found that SUV_max from PET/CT had the best diagnostic efficacy in identifying malignancy, while PET/MR showed higher specificity and accuracy for M-stage. The treatment strategy and WBTLG were independent prognostic factors in pancreatic neoplasm patients. PET/MR using the background method was identified as the optimal predictive model for prognosis.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":"13 6","pages":"269-278"},"PeriodicalIF":2.5,"publicationDate":"2023-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10774601/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139416099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dive into the details of radionuclide antibody conjugates: what role do EPR effects and LETs of different radionuclides play?","authors":"Sixuan Cheng, Dawei Jiang, Mengting Li","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Radionuclide antibody conjugate (RAC) is a promising diagnostic and therapeutic tool. It combines radionuclides and antibodies by connecting arms and chelating agents, offering precise targeting and potent killing of tumor cells. However, further development and optimization of this radiopharmaceutical is needed to enhance the ultimate substantive efficacy for clinical translation. In this issue of AJNMMI, Strand et al. evaluated the enhanced permeability effect and different linear energy transfer (LET) of radionuclides in a prostate cancer xenograft model. The results showed that specific targeting might negatively influence normal organ uptake when targeting secreted antigens and different LETs of radionuclides might have diverse effects on receptor expression and cell proliferation in tumors. The findings provide new thinking for the development of antibody-based radiopharmaceuticals.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":"13 6","pages":"295-299"},"PeriodicalIF":2.5,"publicationDate":"2023-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10774602/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139416100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Malignant melanoma of gastrointestinal tract on ¹⁸F-FDG PET/CT: three case reports.","authors":"Wenpeng Huang, Yongkang Qiu, Xiaoyan Xiao, Liming Li, Qi Yang, Jianbo Gao, Lei Kang","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Primary malignant melanoma most frequently occurs in the skin. Melanoma affecting the gastrointestinal (GI) tract has been substantiated for lesions occurring in the esophagus, stomach, small bowel, and anorectum through multiple published reports, given the presence of melanocytes in these areas. Nevertheless, owing to the exceedingly low incidence of this disease, reports on its clinical features are few, and treatment approaches lack standardization. In this study, we present three cases of GI melanoma with imaging manifestations, emphasizing the pivotal role of ¹⁸F-FDG PET/CT in staging for GI melanoma. Establishing a definitive diagnosis of primary GI melanoma necessitates the exclusion of the possibility of metastasis from more prevalent primary sites. Advancements in molecular imaging technologies and the development of novel tracers provided significant promising methods for enhancing the diagnosis and management of melanoma, contributing to improved patient outcomes and overall disease management.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":"13 6","pages":"279-288"},"PeriodicalIF":2.5,"publicationDate":"2023-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10774603/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139416101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multimodality imaging of an unusual giant cell tumor of thoracic spine with mediastinal invasion: a case report.","authors":"Wenpeng Huang, Yushuo Peng, Yongbai Zhang, Fangfang Chao, Liming Li, Yongkang Qiu, Jianbo Gao, Lei Kang","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Giant cell tumor (GCT) is a benign yet locally aggressive bone neoplasm typically situated in the juxta-articular metaphysis of long bones. Although spinal involvement is rare, it is predominantly reported in the axial skeleton, with the sacrum being the primary location. Conversely, GCTs are notably uncommon in the thoracic spine. In this report, we present computed tomography (CT), magnetic resonance imaging (MRI), and 2-Deoxy-2-[fluorine-18]-fluoro-D-glucose (¹⁸F-FDG) positron emission tomography combined with computed tomography (PET/CT) multimodality imaging findings of a 36-year-old woman diagnosed with a GCT of the thoracic spine. CT scans provide a precise evaluation of cortical thinning and penetration. While MRI lacks specific diagnostic indicators for GCT, it remains invaluable for delineating the extent of soft tissue expansion and the tumor's relationship with intraspinal neural elements - critical information for surgical planning. ¹⁸F-FDG PET/CT effectively illustrates the lesion's hypermetabolic and locally aggressive characteristics. It is noteworthy that GCT occasionally exhibits metastatic malignant potential, underscoring the value of FDG PET as a pivotal modality for staging, restaging, or assessing therapy response, and for monitoring the efficacy of radiotherapy. Familiarity with the imaging features of GCT is essential for physicians to avoid misinterpretation. This tumor should be considered in the differential diagnosis of spinal tumors, distinguishing it from bone metastases or neurogenic tumors.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":"13 6","pages":"289-294"},"PeriodicalIF":2.5,"publicationDate":"2023-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10774605/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139416102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application of quantitative orbital analysis to assess the activity of Graves' ophthalmopathy.","authors":"Shuang Li, Yue-Jun Liu","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>This study aimed to evaluate the diagnostic value of uptake ratios in the extraocular muscles (EOMs), lacrimal glands, and optic nerves to detect the inflammation activity of Graves' ophthalmopathy (GO) using quantitative analysis of 99m technetium (^99mTc)-labeled diethylene triamine pentaacetic acid (DTPA) orbital single-photon emission computed tomography/computed tomography (SPECT/CT) images. The patients were categorized into an active stage (clinical activity score ≥ 3/7, n=23) or an inactive stage (clinical activity score < 3/7, n=38), based on their clinical activity score. The uptake ratio was manually determined by placing a region of interest within the area of highest uptake, as agreed upon by consensus, in the EOMs, lacrimal gland, and optic nerve on SPECT images corrected for CT attenuation. Patients with active GO exhibited significantly higher uptake ratios in the EOMs, lacrimal glands, and optic nerves compared to patients with inactive GO (all P < 0.01). These parameters have been proven effective in differentiating between active and inactive disease.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":"13 6","pages":"259-268"},"PeriodicalIF":2.5,"publicationDate":"2023-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10774606/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139416087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}